Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Surapaneni S, Yerramilli U, Bai A, Dalvie D, Brooks J, Wang X, Selkirk JV, Yan YG, Zhang P, Hargreaves R, Kumar G, Palmisano M, Tran JQ. Surapaneni S, et al. Among authors: dalvie d. Drug Metab Dispos. 2021 May;49(5):405-419. doi: 10.1124/dmd.120.000220. Epub 2021 Mar 4. Drug Metab Dispos. 2021. PMID: 33674268 Clinical Trial.
Investigation into MAO B-Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B.
Bai A, Shanmugasundaram V, Selkirk JV, Surapaneni S, Dalvie D. Bai A, et al. Among authors: dalvie d. Drug Metab Dispos. 2021 Aug;49(8):601-609. doi: 10.1124/dmd.121.000447. Epub 2021 May 19. Drug Metab Dispos. 2021. PMID: 34011531
Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
Selkirk JV, Dines KC, Yan YG, Ching N, Dalvie D, Biswas S, Bortolato A, Schkeryantz JM, Lopez C, Ruiz I, Hargreaves R. Selkirk JV, et al. Among authors: dalvie d. J Pharmacol Exp Ther. 2021 Dec;379(3):386-399. doi: 10.1124/jpet.121.000741. Epub 2021 Sep 17. J Pharmacol Exp Ther. 2021. PMID: 34535564
Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
Prakash C, Chen W, Rossulek M, Johnson K, Zhang C, O'Connell T, Potchoiba M, Dalvie D. Prakash C, et al. Among authors: dalvie d. Drug Metab Dispos. 2008 Oct;36(10):2064-79. doi: 10.1124/dmd.108.022277. Epub 2008 Jul 24. Drug Metab Dispos. 2008. PMID: 18653742
Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
Dalvie D, Cosker T, Boyden T, Zhou S, Schroeder C, Potchoiba MJ. Dalvie D, et al. Drug Metab Dispos. 2008 Sep;36(9):1869-83. doi: 10.1124/dmd.108.022566. Epub 2008 Jun 19. Drug Metab Dispos. 2008. PMID: 18566038
80 results